While weight loss therapies such as glucagon-like peptide-1 (GLP-1) agonists can be used to treat many patients with type 2 diabetes, identification of new targets may benefit individuals for whom weight loss drugs are contraindicated. Here, GCG is linked to type 2 diabetes mellitus.